Analyst Reco. UroGen Pharma Ltd.

Equities

URGN

IL0011407140

Real-time Estimate Cboe BZX Other stock markets 17:19:05 09/05/2024 BST			5-day change	1st Jan Change
13.04 ^USD	-1.70%		-9.01%	-13.50%

05-07	Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates	MT
05-05	UroGen Pharma Ltd. Reports on New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oppenheimer Adjusts UroGen Pharma Price Target to $34 From $35, Maintains Outperform Rating	03-15	MT
Oppenheimer Adjusts UroGen Pharma Price Target to $35 From $32, Maintains Outperform Rating	01-24	MT
Oppenheimer Adjusts UroGen Pharma Price Target to $32 From $33, Maintains Outperform Rating	11-15	MT
HC Wainwright Adjusts Price Target on UroGen Pharma to $54 From $23, Maintains Buy Rating	01/08/23	MT
Goldman Sachs Adjusts UroGen Pharma Price Target to $18 From $11, Maintains Neutral Rating	31/07/23	MT
Oppenheimer Adjusts UroGen Pharma Price Target to $33 From $22, Maintains Outperform Rating	28/07/23	MT
Jefferies Downgrades UroGen Pharma to Hold From Buy, Adjusts Price Target to $10 From $35	08/02/23	MT
HC Wainwright Adjusts UroGen Pharma's Price Target to $23 From $26, Keeps Buy Rating	12/12/22	MT
UroGen Highlights New Real-World Safety Data Published in The British Journal of Urology International That Showed a Low Rate of Ureteral Stenosis When Antegrade Administration of JELMYTO® was Used in Patients with Upper Tract Urothelial Carcinoma	14/11/22	CI
Oppenheimer Adjusts UroGen Pharma Price Target to $35 From $21, Maintains Outperform Rating	12/08/22	MT
Berenberg Bank Terminates Coverage of 85 Companies in Consumer Discretionary, Healthcare, Industrial Tech, REIT, Software and IT Services Sectors	01/07/22	MT
Berenberg Bank Initiates Coverage on UroGen Pharma With Buy Rating, $20 Price Target	27/04/22	MT
Oppenheimer Adjusts UroGen Pharma Price Target to $21 From $30, Maintains Outperform Rating	26/04/22	MT
Goldman Sachs Adjusts UroGen Pharma's Price Target to $11 from $10, Maintains Neutral Rating	22/03/22	MT
HC Wainwright Adjusts UroGen Pharma's Price Target to $26 From $34, Reiterates Buy Rating	22/03/22	MT
HC Wainwright Adjusts UroGen Pharma's Price Target to $34 From $50, Reiterates Buy Rating	18/01/22	MT
UROGEN PHARMA : Goldman Sachs Adjusts Price Target for UroGen Pharma to $27 From $26, Maintains Neutral Rating	16/07/21	MT
UROGEN PHARMA : Oppenheimer Adjusts UroGen Pharma's Price Target to $30 From $34, Maintains Outperform Rating	14/05/21	MT
UROGEN PHARMA : HC Wainwright Adjusts Price Target on UroGen Pharma to $50 From $57, Maintains Buy Rating	27/04/21	MT
UROGEN PHARMA : Oppenheimer Adjusts UroGen Pharma PT to $34 From $40, Maintains Outperform Rating	19/03/21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. UroGen Pharma Ltd.

Equities

URGN

IL0011407140

Analyst Reco.

Filters